Long-term open-label extension study of bexicaserin in developmental and epileptic encephalopathies

Phase 3, open-label, single-arm trial of bexicaserin in epileptic encephalopathy, Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Longboard Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Changes in safety laboratory parameters and 5 more. Planned start Oct 2025; status: authorised.